The biomarker is not the end.
As drug discovery and translational scientists think about using stratification with biomarkers to improve the chances of getting medicines to patients, several areas of expertise need to be considered. These include analytical validation, clinical validation, regulatory affairs and intellectual property. Getting the right input from the right expert at the right time can make or break an effort to bring a biomarker-based companion diagnostic successfully into clinical practice.